Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy

OncoImmunology

Volumn 7, Issue 7, 2018, Pages

  Yue, Chunyan ^a,c   Jiang, Yubo ^b   Li, Ping ^a   Wang, Yuehua ^a   Xue, Jian ^d   Li, Nannan ^d   Li, Da ^d   Wang, Ruina ^f,g   Dang, Yongjun ^f,g   Hu, Zhiyuan ^a,c,e   Yang, Yanlian ^a,c   Xu, Jianming ^b  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d Nanopep Biotech Co   (China)

^e FUJIAN MEDICAL UNIVERSITY   (China)

^f FUDAN UNIVERSITY   (China)

^g FUDAN UNIVERSITY   (China)

Author keywords

advanced solid tumor; circulating tumor cells (CTCs); immunotherapy; programmed death ligand 1 (PD L1); semi quantitative analysis

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BIOLOGICAL MARKER; CHECKPOINT KINASE INHIBITOR; IBI 308; KN 802; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FLOW CYTOMETRY; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN EXPRESSION LEVEL; SENSITIVITY AND SPECIFICITY; SOLID MALIGNANT NEOPLASM; TREATMENT RESPONSE;

EID: 85042918868     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2018.1438111     Document Type: Article

References (47)

1. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers and combinations. Sci Translational Med. 2016;8:328rv4–rv4. doi:10.1126/scitranslmed.aad7118
2. Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci. 2017;24:15. doi:10.1186/s12929-016-0311-y. PMID:28219375.
3. Hwang YY, Khong PL, Kwong YL. Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol. 2017;96:1219–20. doi:10.1007/s00277-017-3007-9. PMID:28434018.
4. Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, Goldberg KB, Kim G, Pazdur R. U.S. food and drug administration approval summary: Atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res. 2017;23(16):4534–4539. doi:10.1158/1078-0432.CCR-17-0540. PMID:28611199.
5. Maraz A, Geczi L. [The role of immunotherapy in the modern treatment of urothelial carcinoma]. Magyar Onkologia. 2017;61:139–46. PMID:28585615.
6. Beckermann KE, Johnson DB, Sosman JA. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol. 2017;13:77–84. doi:10.1080/1744666X.2016.1214575. PMID:27426025.
7. Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol. 2017;35(12):701–707. doi:10.1016/j.urolonc.2017.08.005. PMID:28889921.
8. Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol. 2017;10:110. doi:10.1186/s13045-017-0479-y. PMID:28514966.
9. Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational Lung Cancer Res. 2015;4:743–51.
10. Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Rev Oncol/Hematol. 2016;100:88–98. doi:10.1016/j.critrevonc.2016.02.001
11. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46–54. doi:10.1001/jamaoncol.2015.3638. PMID:26562159.
12. Bardelli A, Pantel K. Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell. 2017;31:172–9. doi:10.1016/j.ccell.2017.01.002. PMID:28196593.
13. Khoo BL, Grenci G, Jing T, Lim YB, Lee SC, Thiery JP, Han J, Lim CT. Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv. 2016;2:e1600274. doi:10.1126/sciadv.1600274. PMID:27453941.
14. Mu Z, Benali-Furet N, Uzan G, Znaty A, Ye Z, Paolillo C, Wang C, Austin L, Rossi G, Fortina P, et al. Detection and characterization of circulating tumor associated cells in metastatic breast cancer. Int J Mol Sci. 2016;17:E1665. doi:10.3390/ijms17101665. PMID:27706044.
15. Wang Y, Zhou Y, Hu Z. The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement. J Translational Int Med. 2017;5:135–8.
16. Oliveira-Costa JP, de Carvalho AF, da Silveira GG, Amaya P, Wu Y, Park K-JJ, Gigliola MP, Lustberg M, Buim ME, Ferreira EN, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget. 2015;6:20902–20. doi:10.18632/oncotarget.3939. PMID:26041877.
17. Wang X, Sun Q, Liu Q, Wang C, Yao R, Wang Y. CTC immune escape mediated by PD-L1. Medical Hypotheses. 2016;93:138–9. doi:10.1016/j.mehy.2016.05.022. PMID:27372873.
18. Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 2016;16:744. doi:10.1186/s12885-016-2758-3.
19. Kulasinghe A, Perry C, Kenny L, Warkiani ME, Nelson C, Punyadeera C. PD-L1 expressing circulating tumour cells in head and neck cancers. BMC Cancer. 2017;17:333. doi:10.1186/s12885-017-3316-3. PMID:28511705.
20. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9:1773–82. doi:10.1016/j.molonc.2015.05.009. PMID:26093818.
21. Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726. doi:10.1038/srep31726. PMID:27553175.
22. Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep. 2016;6:28910. doi:10.1038/srep28910. PMID:27363678.
23. Bai L, Du Y, Peng J, Liu Y, Wang Y, Yang Y, et al. Peptide-based isolation of circulating tumor cells by magnetic nanoparticles. J Materials Chem B. 2014;2:4080–8. doi:10.1039/C4TB00456F
24. Liu XR, Shao B, Peng JX, Li HP, Yang YL, Kong WY, Song GH, Jiang HF, Liang X, Yan Y. Identification of high indepen-dent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. Breast. 2017;32:119–25. doi:10.1016/j.breast.2017.01.007. PMID:28157583.
25. Wang W, Li H, Xu F, Du H, Li X, Yi J, Wang G, Luan X. [IFN-gamma up-regulates PD-L1 expression in human placenta mesenchymal stem cells and enhances cell ability to induce the differentiation of IL-10+ T cells from cord blood- and peripheral blood-derived T cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32:191–5. PMID:26927379.
26. Li H, Wang W, Wang G, Hou Y, Xu F, Liu R, Wang F, Xue J, Hu T, Luan X. Interferon-gamma and tumor necrosis factor-alpha promote the ability of human placenta-derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4(+)interleukin-10(+) and CD8(+)interleukin-10(+)Treg subsets. Cytotherapy. 2015;17:1560–71. doi:10.1016/j.jcyt.2015.07.018. PMID:26432559.
27. Poreau B, Sartelet H. Placenta avec mélanome métastatique: un nouveau cas avec expression de PDL1. Annales De Pathologie. 2017;37:338. doi:10.1016/j.annpat.2017.05.005. PMID:28754220.
28. Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. Int J Gynecol Pathol. 2017;36:146–53. PMID:27362903.
29. Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treatment Rev. 2015;41:868–76. doi:10.1016/j.ctrv.2015.11.001
30. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Therapeutics. 2015;14:847–56. doi:10.1158/1535-7163.MCT-14-0983
31. Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547:413–8. doi:10.1038/nature23270. PMID:28723893.
32. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67:4–17. doi:10.1016/j.molimm.2015.02.009. PMID:25749122.
33. Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Critical Rev Oncol Hematol. 2016;101:75–85. doi:10.1016/j.critrevonc.2016.03.007
34. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, England). 2016;387:1837–46. doi:10.1016/S0140-6736(16)00587-0. PMID:26970723.
35. Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Rev Oncol/Hematol. 2016;100:88–98. doi:10.1016/j.critrevonc.2016.02.001
36. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 2016; 387:1540–50. doi:10.1016/S0140-6736(15)01281-7. PMID:26712084.
37. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–20. doi:10.1158/1078-0432.CCR-15-1678. PMID:26880610.
38. Efficacy of PD-1 blockade in tumors with MMR deficiency. Immunotherapy. 2016;8:1–3. doi:10.2217/imt.15.97. PMID:26643016.
39. Lu D, Krupa R, Premasekharan G, Hough J, Edwards M, Paz R, et al. BMC Cancer.
40. Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7:10215–27. doi:10.18632/oncotarget.7143. PMID:26848870.
41. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18:1182–91. doi:10.1016/S1470-2045(17)30422-9. PMID:28734759.
42. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509–20. doi:10.1056/NEJMoa1500596. PMID:26028255.
43. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711. doi:10.1016/j.immuni.2016.02.025. PMID:26982367.
44. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol. 2012;23 Suppl 8:viii47–52. doi:10.1093/annonc/mds263. PMID:22918928.
45. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30. doi:10.1200/JCO.2013.53.0105. PMID:24590637.
46. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91. doi:10.1158/2159-8290.CD-15-1483. PMID:26969689.
47. Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Ann Rev Med. 2012;63:199–215. doi:10.1146/annurev-med-062310-094219. PMID:22053740.